(Q38106621)

29 August 2017

title

Targeting inflammasomes in rheumatic diseases (English)

1 reference

29 August 2017

1 reference

3

Leo A B Joosten

1 reference

29 August 2017

Alexander So

1

1 reference

29 August 2017

Annette Ives

series ordinal

2

1 reference

29 August 2017

Nathalie Busso

series ordinal

4

1 reference

29 August 2017

language of work or name

English

0 references

publication date

14 May 2013

1 reference

Nature Reviews Rheumatology

29 August 2017

published in

1 reference

29 August 2017

volume

9

1 reference

29 August 2017

issue

7

1 reference

29 August 2017

page(s)

391-399

1 reference

https://scigraph.springernature.com/pub.10.1038/nrrheum.2013.61

29 August 2017

exact match

0 references

cites work

The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Sensing and reacting to microbes through the inflammasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The inflammasome: an integrated view

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammasomes in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Critical role for calcium mobilization in activation of the NLRP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Cutting edge: NF-kappaB activating pattern recognition and cytokine receptors license NLRP3 inflammasome activation by regulating NLRP3 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Superoxide dismutases: ancient enzymes and new insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

ER stress activates the NLRP3 inflammasome via an UPR-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Mitochondrial reactive oxygen species drive proinflammatory cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Interplay between redox status and inflammasome activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

A role for mitochondria in NLRP3 inflammasome activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Basic calcium phosphate crystals induce monocyte/macrophage IL-1β secretion through the NLRP3 inflammasome in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The Nalp3 inflammasome is essential for the development of silicosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Reactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Thioredoxin-interacting protein links oxidative stress to inflammasome activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

P2X7 receptor differentially couples to distinct release pathways for IL-1beta in mouse macrophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Pannexin-1-Mediated Recognition of Bacterial Molecules Activates the Cryopyrin Inflammasome Independent of Toll-like Receptor Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Activation of the NALP3 inflammasome is triggered by low intracellular potassium concentration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Liaisons dangereuses: P2X(7) and the inflammasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca2+ and cAMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Extracellular Ca2+ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

GBP5 promotes NLRP3 inflammasome assembly and immunity in mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Novel role of PKR in inflammasome activation and HMGB1 release

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Use of canakinumab in the cryopyrin-associated periodic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Altered redox state of monocytes from cryopyrin-associated periodic syndromes causes accelerated IL-1beta secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Successful treatment of acute visual loss in Muckle-Wells syndrome with interleukin 1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Gout-associated uric acid crystals activate the NALP3 inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

A pilot study of IL-1 inhibition by anakinra in acute gout

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

A pilot study of IL-1 inhibition in acute calcific periarthritis of the shoulder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Synovial fluid analysis for diagnosis of intercritical gout.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Purine-rich foods intake and recurrent gout attacks

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Alcohol intake and risk of incident gout in men: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Deficiency of the NF-kappaB inhibitor caspase activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

CARD8 p.C10X polymorphism is associated with inflammatory activity in early rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Association study of CARD8 (p.C10X) and NLRP3 (p.Q705K) variants with rheumatoid arthritis in French and Tunisian populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Common genetic variations in the NALP3 inflammasome are associated with delayed apoptosis of human neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The Q705K polymorphism in NLRP3 is a gain-of-function alteration leading to excessive interleukin-1β and IL-18 production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammasome-independent role of apoptosis-associated speck-like protein containing a CARD (ASC) in T cell priming is critical for collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

ASC plays a role in the priming phase of the immune response to type II collagen in collagen-induced arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

ASC-mediated NF-kappaB activation leading to interleukin-8 production requires caspase-8 and is inhibited by CLARP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Mechanism and repertoire of ASC-mediated gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Expression and function of the NALP3 inflammasome in rheumatoid synovium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Expression and regulation of cryopyrin and related proteins in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Arguments for interleukin 1 as a target in chronic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Calcification of articular cartilage in human osteoarthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Aspergillus fumigatus stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Fungal zymosan and mannan activate the cryopyrin inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Borrelia species induce inflammasome activation and IL-17 production through a caspase-1-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

How the study of children with rheumatic diseases identified interferon-alpha and interleukin-1 as novel therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Autoinflammatory gene mutations in Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Dysfunctional inflammasome in Schnitzler's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

The emerging role of interleukin-1β in autoinflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Octacalcium phosphate crystals induce inflammation in vivo through interleukin-1 but independent of the NLRP3 inflammasome in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

NLRP1-dependent pyroptosis leads to acute lung injury and morbidity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Anthrax lethal factor cleavage of Nlrp1 is required for activation of the inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Critical role of AIM2 in Mycobacterium tuberculosis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

AIM2/ASC triggers caspase-8-dependent apoptosis in Francisella-infected caspase-1-deficient macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Enhanced inflammatory responses of chronic granulomatous disease leukocytes involve ROS-independent activation of NF-kappa B

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Superoxide dismutase 1 regulates caspase-1 and endotoxic shock

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Genetic variation in proteins of the cryopyrin inflammasome influences susceptibility and severity of rheumatoid arthritis (The Swedish TIRA project)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Inflammatory Role of ASC in Antigen-Induced Arthritis Is Independent of Caspase-1, NALP-3, and IPAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Stress-induced cartilage degradation does not depend on the NLRP3 inflammasome in human osteoarthritis and mouse models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

(S)-1-((S)-2-{[1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoyl)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2013.61

31 March 2020

Identifiers

DOI

10.1038/NRRHEUM.2013.61

1 reference

Dimensions Publication ID

29 August 2017

1035638963

0 references

1 reference